Navigation Links
Leukemia drug could save lives of stroke patients
Date:6/22/2008

(New York, June 22). The drug tPA is the most effective treatment currently available for stroke patients, but its safety is limited to use within the first three hours following the onset of symptoms. After that, tPA may cause dangerous bleeding in the brain. However, in a study published today in Nature Medicine, investigators from the Stockholm Branch of the Ludwig Institute for Cancer Research (LICR) and the University of Michigan Medical School show that these problems might be overcome if tPA is combined with the leukemia drug, imatinib (Gleevec). The results demonstrate that imatinib greatly reduces the risk of tPA-associated bleeding in mice, even when tPA was given as late as five hours after the stroke had begun. The LICR team, in collaboration with the Karolinska University Hospital in Stockholm, is now planning a clinical trial with imatinib in stroke patients.

According to the World Health Organization (WHO), 80 percent of the 15 million strokes that occur each year are caused by the type of blood clots in the brain that tPA can dissolve. Today, less than 3% of patients with this type of stroke receive tPA because the narrow safety window has often passed by the time a stroke patient reaches a hospital and is diagnosed. If the planned clinical trial with stroke patients in Sweden confirms the findings of the present study, there is great promise that imatinib or similar drugs could be administered to stoke patients to increase the therapeutic window of tPA.

The basis for this novel proposal is the key growth factor PDGF-CC, which has now been discovered to control the blood brain barrier (a structure that normally shields the brain from the blood). When tPA acts on PDGF-CC, the blood-brain barrier becomes porous and can start to leak. Imatinib inhibits the detrimental effect of PDGF-CC by binding to its receptor PDGFR alpha, seemingly without hindering tPA's therapeutic effect, which is to break down clots that have lodge
'/>"/>

Contact: Sarah White
swhite@licr.org
917-379-0398
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. Study finds heart failure is rare among leukemia patients on imatinib
3. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. Novel strategy under study for aggressive leukemia
7. Drug has ability to cure type of leukemia
8. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
9. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
11. St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... of scientists led by a researcher from the Cancer ... University of Singapore has identified the cancer specific stem ... the possibility of developing new drugs for the treatment ... The research group, led by Dr Chan Shing Leng, ... first time that a cancer-specific variant of a cell ...
(Date:4/23/2014)... also known as Ritalin, may prevent the depletion of ... , a journal of the Association for Psychological Science. ... diet or trying to focus attention on a boring ... one potential explanation for this difficulty: Exerting self-control for ... exert self-control effectively on subsequent tasks. , "It is ...
(Date:4/22/2014)... the New Jersey Institute of Technology (NJIT) today ... the launch of the New Jersey Innovation Institute ... model for business innovation through the leveraging of ... U.S. Senator Cory Booker, Panasonic Corp. of North ... Lieutenant Governor Kim Guadagno, New Jersey Secretary of ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making ... . , A team of physician-scientists at UT ... (a hormone with natural anti-depressant properties) works inside the ... treatment for depression in the form of a neuroprotective ... published online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... (April 22, 2014) The International Communication Association ... in Seattle, Washington. The theme of the 2014 ... in a networked and digital society. , Featuring ... by over 2,200 Communication scholars representing over 40 ... international communication conference in the world. This year,s ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... ... ... ... ...
... behind many countries in the use of electronic health ... and political leaders set targets for universal adoption, states ... Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj092189.pdf . ... in federal funds to develop integrated electronic health records, ...
... ... ... ... ...
... ... ... , ... HOUSTON , March 1 Despite Northstar ...
... ... Position , ... Ariz. (Vocus) February 28, 2010 -- Tom Rios has been promoted to Executive Director ... he had been Splendido’s director of accounting., , ,Rios will work with managers and ...
... ... ... ... ...
Cached Medicine News:Health News:Chlorella: A Green Whole Food That Can Help Improve the American Diet 2Health News:Chlorella: A Green Whole Food That Can Help Improve the American Diet 3Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 2Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 3Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 4Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 5Health News:Northstar Management Forecasts a Loss of $1.2 Million for 2010 at Its Palladium for Surgery -- Houston, Ltd. Centre 2Health News:Tom Rios Named Executive Director at Splendido 2Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 2Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 3Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 4Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 5Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 7
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... new survey shows almost half (44%) of U.S. patients ... acute pain. (Logo: http://photos.prnewswire.com/prnh/20110816/DC52192LOGO-b ) ... Pain (P3) Survey, one of the largest pain management ... also show that this undertreatment was particularly prevalent among ...
... 2011 Cohera Medical, Inc.®, a rapidly growing medical ... Mark approval for its lead product, TissuGlu® ... to be sold in the European Union. ... large flap surgeries, such as abdominoplasties, that helps reduce ...
Cached Medicine Technology:New Survey Shows Moderate-to-Severe Acute Pain is Widely Undertreated, Especially Among Older Adults 2Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 2Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: